Lopinavir/ritonavir as part of schemes of HAARt in HIV-positive pregnant women and women of reproductive age: the dynamics of clinical and immunological and virological indicators
https://doi.org/10.22625/2072-6732-2015-7-1-59-64
Abstract
The paper presents the results of an open randomized comparative study of the clinical, immunological and virological efficacy of regimens of HAART, including lopinavir/ritonavir (LPV/RTV – “Kaletra”, Abbvie) pregnant women (n= 104) women and women of reproductive age (n=50) c HIV infection. The incidence of adverse events requiring change therapeutic scheme with the inclusion of LPV/RTV did not exceed 2% in both study groups and did not differ statistically. Despite the fact that in the comparison group women significantly differed more advanced stage of the disease, more severe immunosuppression and high activity of viral replication, HAART using LPV/RTV in this group after four weeks of its implementation was significantly better than in the group of women who received the same therapy on a background of pregnancy. Pharmacokinetics of antiviral drugs during pregnancy may require dose increase in order to achieve more rapid virological response and reduce the risk of vertical transmission of HIV from mother to child.
About the Authors
A. B. Konkova-Reidman
South Ural State Medical University, Chelyabinsk, Russia
Russian Federation
Russian Federation
O. L. Ruhtina
Regional Center for prevention and control of AIDS and infectious diseases, Chelyabinsk, Russia
Russian Federation
Russian Federation
Yu. I. Bulankov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg, Russia
Russian Federation
Russian Federation
References
1. Латышева, И.Б. Стратегия профилактики передачи вируса иммунодефицита человека (ВИЧ-инфекции) от матери ребенку в Российской Федерации на период 2014– 2020 гг. (проект) / И. Б. Латышева, Е. Е. Воронин, Ю.И. Буланьков. – РКИБ-СПб.: Науч.-практ. центр профилактики и лечения ВИЧ-инфекции у беременных женщин и детей, 2014. – 20 с.
2. Афонина, Л.Ю. Клинический протокол «Применение антиретровирусных препаратов в комплексе мер, направленных на профилактику передачи ВИЧ от матери ребенку» / Л.Ю. Афонина [и др.] // Эпидемиология и инфекционные болезни. – 2013. – No 1–54 с.
3. Беляков, Н.А. Женщина, ребенок и ВИЧ / Н.А. Беляков, Н.Ю. Рахманина, А.Г. Рахманова. – СПб.: Балтийский Медицинский Образовательный Центр, 2012. – 600 с.
4. Национальные клинические рекомендации по диагностике и лечению ВИЧ-инфекции у взрослых / А.И. Мазус [и др.]. — М., 2014. — 75 c.
5. Сизова, Н.В. Назначение антиретровирусной терапии женщинам в различные периоды жизни / Н. В. Сизова, А. В. Самарина, Г. А. Ефимов // ВИЧ-инфекция и иммуносупрессии. – 2013. – Т. 5, No 3. – С. 34–42.
6. Бартлетт, Дж. Клинические аспекты ВИЧ-инфекции 2012 / Дж. Бартлетт, Дж. Галлант, П. Фам. – М.: Р. Валент, 2012 – 528 с.
7. Tookey P, Thorne C, Martinez-Tristani M, Norton M. Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r). J Int AIDS Soc. 2014 Nov;21(7):809-816.
8. Cressey TR, Urien S, Capparelli EV, Best BM. Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy. J Antimicrob Chemother. 2014 Sep;49:485– 491.
9. Santini-Oliveira M, Estrela Rde C, Veloso VG, Cattani VB. Randomized clinical trial comparing the pharmacokinetics of standardand increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women. J Antimicrob Agents Chemother. 2014 May;17(3):324–331.
10. Hermes A, Squires K, Fredrick L, Martinez M. Metaanalysis of the safety, tolerability, and efficacy of lopinavir/ ritonavir-containing antiretroviral therapy in HIV-1-infected women. HIV Clin Trials. 2012 Nov-Dec;13(6):308-23.
11. Umeh OC, Currier JS, Park JG, Cramer Y. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol. 2011 Dec;8(6):371-80.
12. Murphy RL, da Silva BA, Hicks CB, Eron JJ. Sevenyear efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2008 Jan;9(1):1-10.
13. Gathe J, da Silva BA, Cohen DE. A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks. J Acquir Immune Defic Syndr. 2009 Sep;50(5):474-81
14. Zajdenverg B., Podsadeck TJ, Sharlaa Badal-Faesen S. Similar Safety and Efficacy of Onceand Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1–Infected Subjects at 48 Weeks. J Acquir Immune Defic Syndr. 2010 Jan;43(9):771-39
15. Recommendation for use ARV drugs in pregnant HIVinfected women for maternal health and interventions to reduce perinatal HIV transmission in the US [Internet]. Perinatal HIV Guidelines Working Group, 2013. Available from: http://aidsinfo.nih.gov/guidelines
16. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults [Internet]. 2013. Available from: http://www.eacsociety.org/ guidelines/eacs-guidelines/eacs-guidelines.html
17. Латышева, И.Б. Ингибиторы протеазы в схемах медикаментозной профилактики передачи ВИЧ-инфекции от матери к ребенку / И.Б. Латышева [и др.] // Инфекционные болезни: новости, мнения, обучение. – 2014. – No 2. – С. 15–20.
18. Беляева, В.В. Приверженность высокоактивной антиретровирусной терапии при ВИЧ-инфекции: пособие для врачей / В.В. Беляева, А.В. Кравченко. – М., 2004. – 42 с.
Review
For citations:
Konkova-Reidman A.B., Ruhtina O.L., Bulankov Yu.I. Lopinavir/ritonavir as part of schemes of HAARt in HIV-positive pregnant women and women of reproductive age: the dynamics of clinical and immunological and virological indicators. Journal Infectology. 2015;7(1):59-64. (In Russ.) https://doi.org/10.22625/2072-6732-2015-7-1-59-64
Views:
953
.png)
.png)
Email this article 